BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 16818192)

  • 1. Conditionally replicating adenovirus-mediated gene therapy in bladder cancer: an orthotopic in vivo model.
    Melquist JJ; Kacka M; Li Y; Malaeb BS; Elmore J; Baseman AG; Hsieh JT; Koeneman KS
    Urol Oncol; 2006; 24(4):362-71. PubMed ID: 16818192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conditionally replicating adenovirus therapy utilizing bone sialoprotein promoter (Ad-BSP-E1a) in an in vivo study of treating androgen-independent intraosseous prostate cancer.
    Li Y; Kacka M; Thompson M; Hsieh JT; Koeneman KS
    Urol Oncol; 2011; 29(6):624-33. PubMed ID: 19963408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
    Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
    J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Midkine promoter-based conditionally replicative adenovirus for targeting midkine-expressing human bladder cancer model.
    Terao S; Shirakawa T; Kubo S; Bishunu A; Lee SJ; Goda K; Tsukuda M; Hamada K; Tagawa M; Takenaka A; Fujisawa M; Gotoh A
    Urology; 2007 Nov; 70(5):1009-13. PubMed ID: 17919690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis.
    Izawa JI; Sweeney P; Perrotte P; Kedar D; Dong Z; Slaton JW; Karashima T; Inoue K; Benedict WF; Dinney CP
    Clin Cancer Res; 2002 Apr; 8(4):1258-70. PubMed ID: 11948141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of hepatocellular carcinoma with a novel gene-viral therapeutic system CNHK300-murine endostatin].
    Li GC; Nie MM; Yang JM; Su CQ; Sun LC; Qian YZ; Sham J; Fang GE; Wu MC; Qian QJ
    Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):943-8. PubMed ID: 15329284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenovirus-E1A gene therapy enhances the in vivo sensitivity of Ewing's sarcoma to VP-16.
    Zhou RR; Jia SF; Zhou Z; Wang Y; Bucana CD; Kleinerman ES
    Cancer Gene Ther; 2002 May; 9(5):407-13. PubMed ID: 11961663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
    J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer.
    Liao Y; Zou YY; Xia WY; Hung MC
    Cancer Gene Ther; 2004 Sep; 11(9):594-602. PubMed ID: 15272313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
    Chang JY; Xia W; Shao R; Sorgi F; Hortobagyi GN; Huang L; Hung MC
    Oncogene; 1997 Feb; 14(5):561-8. PubMed ID: 9053854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cox-2 promoter-based replication-selective adenoviral vector to target the cox-2-expressing human bladder cancer cells.
    Shirakawa T; Hamada K; Zhang Z; Okada H; Tagawa M; Kamidono S; Kawabata M; Gotoh A
    Clin Cancer Res; 2004 Jul; 10(13):4342-8. PubMed ID: 15240520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model.
    Zhang Y; Yu D; Xia W; Hung MC
    Oncogene; 1995 May; 10(10):1947-54. PubMed ID: 7761095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
    Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
    Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent antitumoral effects of a novel gene-viral therapeutic system CNHK300-mEndostatin in hepatocellular carcinoma.
    Li GC; Yang JM; Nie MM; Su CG; Sun LC; Qian YZ; Fang GE; Sham J; Wu MC; Qian QJ
    Chin Med J (Engl); 2005 Feb; 118(3):179-85. PubMed ID: 15740644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
    Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
    Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-selective replication of an oncolytic adenovirus carrying oct-3/4 response elements in murine metastatic bladder cancer models.
    Wu CL; Shieh GS; Chang CC; Yo YT; Su CH; Chang MY; Huang YH; Wu P; Shiau AL
    Clin Cancer Res; 2008 Feb; 14(4):1228-38. PubMed ID: 18281558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis.
    Matsubara S; Wada Y; Gardner TA; Egawa M; Park MS; Hsieh CL; Zhau HE; Kao C; Kamidono S; Gillenwater JY; Chung LW
    Cancer Res; 2001 Aug; 61(16):6012-9. PubMed ID: 11507044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer.
    Ramesh N; Ge Y; Ennist DL; Zhu M; Mina M; Ganesh S; Reddy PS; Yu DC
    Clin Cancer Res; 2006 Jan; 12(1):305-13. PubMed ID: 16397056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
    Rein DT; Breidenbach M; Kirby TO; Han T; Siegal GP; Bauerschmitz GJ; Wang M; Nettelbeck DM; Tsuruta Y; Yamamoto M; Dall P; Hemminki A; Curiel DT
    Clin Cancer Res; 2005 Feb; 11(3):1327-35. PubMed ID: 15709205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel A33 promoter-based conditionally replicative adenovirus suppresses tumor growth and eradicates hepatic metastases in human colon cancer models.
    Cafferata EG; Macció DR; Lopez MV; Viale DL; Carbone C; Mazzolini G; Podhajcer OL
    Clin Cancer Res; 2009 May; 15(9):3037-49. PubMed ID: 19336523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.